Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

BACKGROUND: Non‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone. US and European lipid management guidelines support non‐HDL‐C and apoB as targets for lipid...

Descripción completa

Detalles Bibliográficos
Autores principales: Bays, Harold E., Leiter, Lawrence A., Colhoun, Helen M., Thompson, Desmond, Bessac, Laurence, Pordy, Robert, Toth, Peter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586424/
https://www.ncbi.nlm.nih.gov/pubmed/28862926
http://dx.doi.org/10.1161/JAHA.117.005639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586424/
https://www.ncbi.nlm.nih.gov/pubmed/28862926
http://dx.doi.org/10.1161/JAHA.117.005639

Ejemplares similares